提高血钾水平降低心房颤动相关临床事件风险:POTCAST试验
POTCAST试验的预设分析纳入1200例植入ICD或CRT-D且血钾≤4.3 mmol/L的成人,随机接受升钾治疗至正常高值或标准治疗。
要点
- 对植入ICD/CRT-D且血钾≤4.3 mmol/L的患者,将血钾提升至正常高值可降低房颤相关临床事件风险。
- 主要终点包括房颤导致住院、 inappropriate shock、电复律/消融住院及胺碘酮负荷。
- 治疗效果在各亚组中一致,包括有无房颤病史者。
核心结论
- 在植入ICD或CRT-D的心脏病患者中,将血钾提升至正常高值可降低房颤相关临床事件风险。
研究设计与样本
- POTCAST试验的预设分析,纳入1200例植入ICD或CRT-D且血钾≤4.3 mmol/L的成人,随机分为正常高值血钾组和对照组。
主要发现
- 中位随访3.3人年,正常高值血钾组主要终点发生48例(8.0%,2.80事件/100人年),对照组73例(12.2%,4.30事件/100人年)。
- 正常高值血钾组血钾较对照组升高0.3 mmol/L。
- 治疗效果在各亚组中相似,包括有无房颤病史者。
临床怎么用
- 对于植入ICD或CRT-D且血钾≤4.3 mmol/L的心脏病患者,可考虑将血钾提升至正常高值以降低房颤相关临床事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hypokalaemia and low-normal plasma potassium levels are associated with increased risk of atrial fibrillation. This study examined if potassium-increasing treatment reduces the risk of atrial fibrillation-related clinical events. METHODS: This is a prespecified analysis of the POTCAST trial. Adults with an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) and plasma potassium ≤4.3 mmol/L were randomized to potassium-increasing treatment and standard care (high-normal potassium group) or standard care alone (control group). The endpoint was a composite of acute hospitalizations due to atrial fibrillation leading to a change in pharmacological treatment or due to inappropriate shock therapy, hospitalization for electrical cardioversion or ablation of atrial fibrillation, and loading with amiodarone for atrial fibrillation. The endpoint was evaluated in time-to-first-event analyses with death as competing risk. RESULTS: Among 1200 participants [600 in each group, median age 64 years (interquartile range, 56-72), 80.3% male], 390 (32.5%) had a history of atrial fibrillation. Plasma potassium increased by .3 mmol/L after uptitration in the high-normal potassium group compared with the controls. After a median follow-up of 3.3 person-years, the endpoint had occurred in 48 participants in the high-normal potassium group (8.0%, 2.80 events per 100 person-years), when compared with 73 participants in the control group (12.2%, 4.30 events per 100 person-years) (subdistribution hazard ratio, .65; 95% confidence interval, .45-.93, P = .02). The treatment effect appeared similar across subgroups, including those with vs without a history of atrial fibrillation. CONCLUSIONS: In adults with any cardiac disease, treated with an ICD or CRT-D, uptitration of plasma potassium levels within the normal range reduced the risk of atrial fibrillation-related clinical events.
引用
- Zheng C, Winsløw UCG, Danielsen EM, et al. Increasing plasma potassium and risk of atrial fibrillation: the POTCAST trial. Eur Heart J. 2026. PMID: 42668425. doi:10.1093/eurheartj/ehag436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。